公开(公告)号：US20170044500A1

公开(公告)日：2017-02-16

申请号：US15306187

申请日：2015-04-24

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Laurence JN COOPER ,  Hiroki TORIKAI

IPC分类号： C12N5/074 ,  A61K39/00 ,  G01N33/566 ,  C12N15/86 ,  C12N5/0789

CPC分类号： C12N5/0696 ,  A61K39/0011 ,  A61K2039/5158 ,  C12N5/0647 ,  C12N15/86 ,  C12N2501/602 ,  C12N2501/603 ,  C12N2501/604 ,  C12N2501/606 ,  C12N2502/1114 ,  C12N2506/45 ,  C12N2510/00 ,  G01N33/566 ,  G01N2333/705 ,  G01N2333/7051

摘要： The application of induced pluripotent stem cells (iPSCs) to generate adoptive cell therapy products and usage of iPSCs for screening potential toxicity of immune receptors are described herein. In some aspects, iPSCs and cells differentiated therefrom are provide which do not express a HLA gene (e.g., HLA-A).

摘要翻译： 本文描述了诱导多能干细胞（iPSCs）在产生过继细胞治疗产品中的用途以及iPSC用于筛选免疫受体的潜在毒性的应用。 在一些方面，提供不表达HLA基因（例如HLA-A）的iPSC和从其分化的细胞。

公开(公告)号：US20200085929A1

公开(公告)日：2020-03-19

申请号：US16543980

申请日：2019-08-19

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Laurence JN COOPER ,  Hiroki TORIKAI ,  Ling ZHANG ,  Helen HULS ,  Feng WANG-JOHANNING ,  Lenka HURTON ,  Simon OLIVARES ,  Janani KRISHNAMURTHY

IPC分类号： A61K39/00 ,  A61P37/00 ,  C07K14/725 ,  A61K35/17 ,  C07K14/54 ,  C07K14/705 ,  C07K16/30

摘要： The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.

公开(公告)号：US20220062396A1

公开(公告)日：2022-03-03

申请号：US17223597

申请日：2021-04-06

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Laurence JN COOPER ,  Hiroki TORIKAI ,  Ling ZHANG ,  Helen HULS ,  Feng WANG-JOHANNING ,  Lenka HURTON ,  Simon OLIVARES ,  Janani KRISHNAMURTHY

IPC分类号： A61K39/00 ,  C07K14/725 ,  A61P37/00 ,  A61K35/17 ,  C07K14/54 ,  C07K14/705 ,  C07K16/30

摘要： The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.

公开(公告)号：US20170224798A1

公开(公告)日：2017-08-10

申请号：US15434595

申请日：2017-02-16

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Laurence JN COOPER ,  Hiroki TORIKAI ,  Ling ZHANG ,  Helen HULS ,  Feng WANG-JOHANNING ,  Lenka HURTON ,  Simon OLIVARES ,  Janani KRISHNAMURTHY

IPC分类号： A61K39/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/30

CPC分类号： A61K39/0011 ,  A61K35/17 ,  A61K2039/505 ,  A61K2039/5158 ,  A61P37/00 ,  C07K14/5443 ,  C07K14/7051 ,  C07K14/70521 ,  C07K16/30 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  Y02A50/411 ,  Y02A50/467

摘要： The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.

公开(公告)号：US20240156929A1

公开(公告)日：2024-05-16

申请号：US18465547

申请日：2023-09-12

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Laurence J.N. COOPER ,  Hiroki TORIKAI ,  Ling ZHANG ,  Helen HULS ,  Feng WANG-JOHANNING ,  Lenka HURTON ,  Simon OLIVARES ,  Janani KRISHNAMURTHY

IPC分类号： A61K39/00 ,  A61K35/17 ,  A61P37/00 ,  C07K14/54 ,  C07K14/705 ,  C07K14/725 ,  C07K16/30

CPC分类号： A61K39/0011 ,  A61K35/17 ,  A61K39/001104 ,  A61K39/001106 ,  A61K39/001109 ,  A61K39/00111 ,  A61K39/001112 ,  A61K39/001113 ,  A61K39/001119 ,  A61K39/001124 ,  A61K39/001129 ,  A61K39/001151 ,  A61K39/001164 ,  A61K39/001168 ,  A61K39/00117 ,  A61K39/001171 ,  A61K39/001174 ,  A61K39/001181 ,  A61K39/001182 ,  A61K39/00119 ,  A61K39/001194 ,  A61P37/00 ,  C07K14/5443 ,  C07K14/7051 ,  C07K14/70521 ,  C07K16/30 ,  A61K2039/505 ,  A61K2039/5158 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  Y02A50/30

摘要： The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.

公开(公告)号：US20230079539A1

公开(公告)日：2023-03-16

申请号：US17929013

申请日：2021-02-10

申请人： Board of Regents, The University of Texas System

发明人： Hiroki TORIKAI ,  Shan ZONG

IPC分类号： A61K39/00 ,  C12N5/071 ,  C12N15/86 ,  C12N15/11 ,  C12N9/22

摘要： The present disclosure provides methods of generating HLA class-I null cells that can be used for expression of exogenous HLA genes and presentation of antigens, such tumor neoantigens. Method for using HLA class-I null cells from selecting, stimulating and propagating immune effector cells are also provided.

公开(公告)号：US20190388472A1

公开(公告)日：2019-12-26

申请号：US16504427

申请日：2019-07-08

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Laurence J. Neil COOPER ,  Hiroki TORIKAI

IPC分类号： A61K35/17 ,  C12N5/0783 ,  A61K39/00

摘要： The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising disrupted T cell receptor and/or HLA and comprising a chimeric antigen receptor. In certain embodiments, the compositions are employed allogeneically as universal reagents for “off-the-shelf” treatment of medical conditions such as cancer, autoimmunity, and infection. In particular embodiments, the T cell receptor-negative and/or HLA-negative T cells are generated using zinc finger nucleases, for example.

公开(公告)号：US20160158285A1

公开(公告)日：2016-06-09

申请号：US14890977

申请日：2014-05-14

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Laurence JN COOPER ,  Hiroki TORIKAI ,  Ling ZHANG ,  Helen HULS ,  Feng WANG-JOHANNING ,  Lenka HURTON ,  Simon OLIVARES ,  Janani KRISHNAMURTHY

IPC分类号： A61K35/17 ,  C07K14/54

CPC分类号： A61K35/17 ,  C07K14/5443 ,  C07K14/7051 ,  Y02A50/411 ,  Y02A50/467

摘要： The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.

摘要翻译： 本发明涉及使用包含嵌合抗原受体（CAR）的修饰T细胞的免疫治疗方法和组合物。 在特定方面，CAR表达的T细胞使用电穿孔与基于转座子的整合系统一起产生，以产生需要最小离体扩增或可直接施用于患者疾病的CAR表达细胞群体（例如 ，癌症）治疗。